Description: Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.
Home Page: www.xspraypharma.com
Råsundavägen 12
Solna,
169 67
Sweden
Phone:
46 87 30 37 00
Officers
| Name | Title |
|---|---|
| Dr. Per Andersson Ph.D. | Chief Exec. Officer |
| Dr. Mustafa Demirbüker Ph.D. | Co-Founder and Science Director |
| Ms. Kerstin Hasselgren | Chief Fin. Officer |
| Mr. Gérald Jesson | VP of Operations |
| Ms. Anna-Karin Ekberg | Sr. VP and Global Head of Marketing & Sales |
| Ms. Charlotta Liljebris | Sr. VP of R&D |
| Dr. Andreas Konar | Sr. VP of Bus. Devel. |
| Mr. Thomas Walz | Chief Medical Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3534 |
| Price-to-Sales TTM: | 1206.1849 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |